日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial

Lutikizumab治疗抗TNF治疗失败的中重度化脓性汗腺炎成人患者：一项II期随机临床试验

期刊:Jama Dermatology
影响因子:11
doi:10.1001/jamadermatol.2026.0155
Kimball, Alexa B; Sawicki, Konrad T; Ackerman, Lindsay; Lima, Hermenio; Giamarellos-Bourboulis, Evangelos J; Zhan, Tianyu; Drogaris, Leonidas; Gu, Yihua; Lee, Christine M; Akbari, Mona; Williams, David A; Bechara, Falk G
发表日期：2026
文献求助 收藏

Improving microbial phylogeny with citizen science within a mass-market video game

利用大众市场电子游戏中的公民科学来改进微生物系统发育

期刊:Nature Biotechnology
影响因子:41.7
doi:10.1038/s41587-024-02175-6
Sarrazin-Gendron, Roman; Ghasemloo Gheidari, Parham; Butyaev, Alexander; Keding, Timothy; Cai, Eddie; Zheng, Jiayue; Mutalova, Renata; Mounthanyvong, Julien; Zhu, Yuxue; Nazarova, Elena; Drogaris, Chrisostomos; Erhart, Kornél; Brouillette, Amélie; Richard, Gabriel; Pitchford, Randy; Caisse, Sébastien; Blanchette, Mathieu; McDonald, Daniel; Knight, Rob; Szantner, Attila; Waldispühl, Jérôme
微生物学
发育与干细胞
发表日期：2025
文献求助 收藏

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

更正：Risankizumab 对 Secukinumab 或 Ixekizumab 疗效欠佳的银屑病患者的疗效和安全性：一项 3b 期开放标签单臂 (aIMM) 研究的结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01328-4
Warren, Richard B; Pavlovsky, Lev; Costanzo, Antonio; Bukhalo, Michael; Korman, Neil J; Huang, Yu-Huei; Kokolakis, Georgios; Pinter, Andreas; Ibrahim, Nadia; Zheng, Yanbing; Drogaris, Leonidas; Stakias, Vassilis; Soliman, Ahmed M; Rubant, Simone; Thaçi, Diamant
银屑病
多发性骨髓瘤
发表日期：2025
文献求助 收藏

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Risankizumab治疗对Secukinumab或Ixekizumab疗效欠佳的银屑病患者的疗效和安全性：一项3b期、开放标签、单臂（aIMM）研究的结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01292-z
Warren, Richard B; Pavlovsky, Lev; Costanzo, Antonio; Bukhalo, Michael; Korman, Neil J; Huang, Yu-Huei; Kokolakis, Georgios; Pinter, Andreas; Ibrahim, Nadia; Zheng, Yanbing; Drogaris, Leonidas; Stakias, Vassilis; Soliman, Ahmed M; Rubant, Simone; Thaçi, Diamant
银屑病
多发性骨髓瘤
发表日期：2024
文献求助 收藏

ARGV: 3D genome structure exploration using augmented reality

ARGV：利用增强现实技术探索三维基因组结构

期刊:BMC Bioinformatics
影响因子:3.3
doi:10.1186/s12859-024-05882-8
Drogaris, Chrisostomos; Zhang, Yanlin; Zhang, Eric; Nazarova, Elena; Sarrazin-Gendron, Roman; Wilhelm-Landry, Sélik; Cyr, Yan; Majewski, Jacek; Blanchette, Mathieu; Waldispühl, Jérôme
发表日期：2024
文献求助 收藏

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial

Risankizumab治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 2随机临床试验的100周结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00657-2
Östör, Andrew; Van den Bosch, Filip; Papp, Kim; Asnal, Cecilia; Blanco, Ricardo; Aelion, Jacob; Carter, Kyle; Stakias, Vassilis; Lippe, Ralph; Drogaris, Leonidas; Soliman, Ahmed M; Chen, Michael M; Padilla, Byron; Kivitz, Alan
关节炎
银屑病
发表日期：2024
文献求助 收藏

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

Risankizumab治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 1 3期随机临床试验的100周结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00654-5
Kristensen, Lars Erik; Keiserman, Mauro; Papp, Kim; McCasland, Leslie; White, Douglas; Carter, Kyle; Lippe, Ralph; Photowala, Huzefa; Drogaris, Leonidas; Soliman, Ahmed M; Chen, Michael; Padilla, Byron; Behrens, Frank
关节炎
银屑病
发表日期：2024
文献求助 收藏

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

比较 risankizumab 和 apremilast 治疗适合接受全身治疗的中度斑块状银屑病成人患者的疗效：一项随机、开放标签、评估者盲法的 IV 期研究 (IMMpulse) 的结果

期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1093/bjd/ljad252
Stein Gold, Linda F; Bagel, Jerry; Tyring, Stephen K; Hong, H Chih-Ho; Pavlovsky, Lev; Vender, Ronald; Pinter, Andreas; Reich, Adam; Drogaris, Leonidas; Wu, Tianshuang; Patel, Manish; Soliman, Ahmed M; Photowala, Huzefa; Stakias, Vassilis; Richter, Sven; Papp, Kim A
银屑病
多发性骨髓瘤
发表日期：2023
文献求助 收藏

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

利沙珠单抗治疗化脓性汗腺炎的疗效和安全性：一项 2 期随机、安慰剂对照试验

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-00913-3
Kimball, Alexa B; Prens, Errol P; Passeron, Thierry; Maverakis, Emanual; Turchin, Irina; Beeck, Stefan; Drogaris, Leonidas; Geng, Ziqian; Zhan, Tianyu; Messina, Izabella; Bechara, Falk G
发表日期：2023
文献求助 收藏

The Mycobacterium tuberculosis regulatory network and hypoxia

结核分枝杆菌调控网络与缺氧

期刊:Nature
影响因子:48.5
doi:10.1038/nature12337
Galagan, James E; Minch, Kyle; Peterson, Matthew; Lyubetskaya, Anna; Azizi, Elham; Sweet, Linsday; Gomes, Antonio; Rustad, Tige; Dolganov, Gregory; Glotova, Irina; Abeel, Thomas; Mahwinney, Chris; Kennedy, Adam D; Allard, René; Brabant, William; Krueger, Andrew; Jaini, Suma; Honda, Brent; Yu, Wen-Han; Hickey, Mark J; Zucker, Jeremy; Garay, Christopher; Weiner, Brian; Sisk, Peter; Stolte, Christian; Winkler, Jessica K; Van de Peer, Yves; Iazzetti, Paul; Camacho, Diogo; Dreyfuss, Jonathan; Liu, Yang; Dorhoi, Anca; Mollenkopf, Hans-Joachim; Drogaris, Paul; Lamontagne, Julie; Zhou, Yiyong; Piquenot, Julie; Park, Sang Tae; Raman, Sahadevan; Kaufmann, Stefan H E; Mohney, Robert P; Chelsky, Daniel; Moody, D Branch; Sherman, David R; Schoolnik, Gary K
信号转导
发表日期：2013
文献求助 收藏